PDCD1 and non-small cell lung carcinoma: The same B7-H3 clone and a similar IHC scoring system were applied by Yonesaka et al. [9] in 82 advanced or recurrent NSCLC patients, of which 50 patients were treated with anti-PD-1 therapy.